QN-02

QN-02 is a preclinical-stage drug candidate being developed by Qnovia (formerly Respira Technologies) for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The drug is designed for pulmonary delivery using Qnovia's proprietary RespiRx platform, which is a portable, orientation-agnostic, breath-activated, vibrating mesh nebulizer (VMN) that utilizes ultrasonic nebulization technology. QN-02 is currently in the formulation and delivery scoping phase, where the company is optimizing the drug's formulation for compatibility with the RespiRx device to ensure precise, metered dosing. While the specific active pharmaceutical ingredient and molecular target for QN-02 have not been publicly disclosed, the program aims to provide a more effective and user-friendly alternative to traditional inhalers by leveraging high-efficiency aerosolization for local lung delivery.